Amyris (NASDAQ:AMRS) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.

Other equities research analysts also recently issued research reports about the company. HC Wainwright set a $15.00 target price on Amyris and gave the company a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research upgraded Amyris from a “hold” rating to a “buy” rating and set a $3.75 price objective on the stock in a report on Wednesday, October 4th. Finally, Cowen reiterated a “hold” rating and issued a $4.00 price objective on shares of Amyris in a report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $20.69.

Amyris (AMRS) traded down $0.05 during trading hours on Friday, reaching $3.58. The company’s stock had a trading volume of 213,705 shares, compared to its average volume of 296,622. Amyris has a 12 month low of $1.86 and a 12 month high of $13.05. The company has a current ratio of 0.92, a quick ratio of 0.82 and a debt-to-equity ratio of -0.78.

Amyris (NASDAQ:AMRS) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04). The business had revenue of $24.20 million during the quarter, compared to the consensus estimate of $36.30 million. During the same quarter in the prior year, the company earned ($0.07) EPS. The firm’s revenue for the quarter was down 8.8% on a year-over-year basis. research analysts predict that Amyris will post -3.32 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of AMRS. Bank of New York Mellon Corp raised its holdings in shares of Amyris by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 4,603 shares during the period. Carl Domino Inc purchased a new stake in shares of Amyris in the 3rd quarter valued at $182,000. KBC Group NV raised its holdings in shares of Amyris by 228.4% in the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 41,834 shares during the period. Finally, Tanaka Capital Management Inc. raised its holdings in shares of Amyris by 72.0% in the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 221,295 shares during the period. Hedge funds and other institutional investors own 26.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Amyris (AMRS) Downgraded by ValuEngine to “Strong Sell”” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/12/03/amyris-amrs-downgraded-by-valuengine-to-strong-sell.html.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.